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repair of ruptured abdominal aortic aneurysm in the
Medicare population
Samuel T. Edwards, Marc L. Schermerhorn, A. James O'Malley,
Rodney P. Bensley, Rob Hurks, Philip Cotterill, Bruce E. Landon
Objective: Endovascular aortic repair (EVAR) for abdomi-
nal aortic aneurysm (AAA) is increasingly used for emergent
treatment of ruptured AAA (rAAA). We sought to compare
the perioperative and long-term mortality, procedure-related
complications, and rates of reintervention of EVAR vs open
aortic repair of rAAA in Medicare beneﬁciaries.
Methods: We examined perioperative and long-term
mortality and complications after EVAR or open aortic repair
performed for rAAA in all traditional Medicare beneﬁciaries
discharged from a United States hospital from 2001 to 2008.
Patients were matched by propensity score on baseline de-
mographics, coexisting conditions, admission source, and
hospital volume of rAAA repair. Sensitivity analyses were
performed to evaluate the effect of bias that might have
resulted from unmeasured confounders.
Results: Of 10,998 patients with repaired rAAA, 1126
underwent EVAR and 9872 underwent open repair. Pro-
pensity score matching yielded 1099 patient pairs. The aver-
age age was 78 years, and 72.4% were male. Perioperative
mortality was 33.8% for EVAR and 47.7% for open repair (P<
.001), and this difference persisted for >4 years. At 36months,
EVARpatients hadhigher rates of AAA-related reinterventions
than open repair patients (endovascular reintervention,
10.9% vs 1.5%; P < .001), whereas open patients had more
laparotomy-related complications (incisional hernia repair,
1.8% vs 6.2%; P < .001; all surgical complications, 4.4% vs
9.1%; P < .001). Use of EVAR for rAAA increased from 6% of
cases in 2001 to 31% in 2008, whereas during the same in-
terval, overall 30-day mortality for admission for rAAA,
regardless of treatment, decreased from 55.8% to 50.9%.
Conclusions: EVAR for rAAA is associated with lower
perioperative and long-term mortality in Medicare beneﬁ-
ciaries. Increasing adoption of EVAR for rAAA is associated
with an overall decrease in mortality of patients hospital-
ized for rAAA during the last decade.A single-center experience of aneurysms in abdominal
organ transplant recipients
David C. Cron, Dawn M. Coleman, Kyle H. Sheetz,
Michael J. Englesbe, Seth A. Waits*Full articles available online at www.jvascsurg.org
1078-5884/$ e see front matter
http://dx.doi.org/10.1016/S1078-5884(14)00045-8Objective: The purpose of this study was to characterize
the prevalence and natural history of aneurysms among
abdominal transplant recipients.
Methods: This article is a retrospective review of adult
patients who underwent a kidney or liver transplant at
a single center between February 23, 2000, and October 6,
2011. Data were obtained by searching electronic medical
records for documentation of arterial aneurysm. Abdominal
aortic aneurysms (AAAs) were included if they were 3.0
cm in diameter, and thoracic aortic aneurysms were inclu-
ded if they had a diameter 3.75 cm. Additional data col-
lected included recipient demographics, transplant-speciﬁc
data, and characteristics of the aneurysms.
Results: There were 927 liver transplant recipients, 2133
kidney transplant recipients, 23 liver-kidney transplant re-
cipients, and 133 kidney-pancreas transplant recipients
included in our study; 127 of these patients were identiﬁed to
have aneurysms (40 liver, 83 kidney, 3 liver-kidney, 1 kidney-
pancreas).The overall prevalence of any aneurysmwas similar
for liver and kidney recipients, but the distribution of aneur-
ysm types was different for the two groups. AAAs made up
29.6% of aneurysms in kidney transplant recipients and 11.4%
of aneurysms in liver transplant recipients (P = .02). Visceral
aneurysms were 10-fold as common in liver transplant re-
cipients comparedwith kidney transplant recipients (47.7% of
aneurysms vs 5.1% of aneurysms; P < .01). The majority of
visceral artery aneurysms involved the hepatic and splenic
artery. For both liver and kidney transplant recipients, most
aneurysms occurred post-transplantation. All known aortic
aneurysm ruptures occurred post-transplantation (25% of
AAAs in liver transplant patients and 22.2% of thoracic aortic
aneurysms in kidney transplant patients). There was a trend
toward higher AAA expansion rates after transplantation
(0.58  0.48 cm/y compared with 0.41  0.16 cm/y).
Conclusions: Compared with the general population,
aneurysms may be more common and may have an
aggressive natural history in abdominal transplant re-
cipients. Furthermore, the types of aneurysms that affect
liver and kidney transplant recipients differ. Care teams
should be aware of these risks and surveillance programs
should be tailored appropriately.Decision analysis model of open repair versus
endovascular treatment in patients with asymptomatic
popliteal artery aneurysms
Wouter Hogendoorn, Felix J.V. Schlösser, Frans L. Moll,
Bart E. Muhs, M.G. Myriam Hunink, Bauer E. Sumpio
Objective: Repair is indicated of asymptomatic popliteal
artery aneurysms (aPAAs) that are >2 cm. Endovascular PAA
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is, however, unclear when an endovascular approach is
preferred to traditional open repair with great saphenous
vein bypass (GSVB). The goal of this study was to assess the
treatment options for aPAAs using decision analysis.
Methods: A Markov model was developed and a hypo-
thetic cohort of patients with aPAAs was analyzed. GSVB,
stenting, and nonoperative management with optimal
medical treatment (OMT) were compared. Operative mor-
tality, patency rates, quality-of-life values, and costs were
determined by comprehensive review of the best available
evidence. The main outcome was quality-adjusted life-years
(QALYs). Secondary outcomes were cost-effectiveness and
number of reinterventions.
Results: For a 65-year-old male patient with a 2.0-cm
aPAA and without signiﬁcant comorbidities, probabilistic
sensitivity analysis shows that intervention is preferred
over OMT (5.77 QALYs, 95% credibility interval [CI], 5.43-
6.11; OMT). GSVB treatment for this patient results in
slightly higher QALYs than stent placement, with a pre-
dicted 8.43 QALYs (GSVB: 95% CI, 8.21-8.64) vs 8.07 QALYs
(stenting: 95% CI, 7.84-8.29), a difference of 0.36 QALYs
(95% CI, 0.14-0.58). Furthermore, costs are higher for
stenting ($40,464; 95% CI, $34,814-$46,242) vs GSVB
($21,618; 95% CI, $15,932-$28,070), and more reinterven-
tions are required after stenting (1.03 per patient) vs GSVB
(0.52 per patient), making GSVB the preferred strategy for
all outcomes considered. Stenting is preferred in patients
who are at high risk for open repair (>6% 30-day mortality)
or if the 5-year primary patency rates of stenting increase
to 80%. For very old patients (>95 years) and patients with
a very short life expectancy (<1.5 years), OMT yields higher
QALYs.
Conclusions: GSVB is the preferred treatment in 65-year-
old patients with aPAAs for all outcomes considered.
However, patients at high risk for open repair or without
suitable vein should be considered as candidates for
endovascular repair. Very elderly patients and patients with
a short life expectancy are best treated with OMT. Further
improvement of endovascular techniques that increase
patency rates of endovascular stents could make this the
preferred therapy for more patients in the future.Lower extremity arterial reconstruction for critical limb
ischemia in diabetes
Enzo Ballotta, Antonio Toniato, Giacomo Piatto,
Franco Mazzalai, Giuseppe Da Giau
Background: The impact of diabetes mellitus on the
technical and clinical outcomes of infrainguinal arterial
reconstruction (IAR) for critical limb ischemia (CLI) remains
controversial. This study analyzed the outcome of IAR in
diabetic patients with CLI over a 17-year period.
Methods: Details on all consecutive patients undergoing
primary IAR at our institution were stored prospectively in
a vascular registry from 1995 to 2011. Demographics, riskfactors, indications for surgery, inﬂow sources and outﬂow
target vessels, types of conduit, and adverse outcomes were
analyzed. Postoperative surveillance included clinical ex-
amination, duplex scans, and ankle-brachial index mea-
surements in all patients at discharge, 1 and 6 months after
surgery, and every 6 months thereafter. End points were
patency, limb salvage, survival, and amputation-free survival
rates, and were assessed using Kaplan-Meier life-table
analysis. The c2 or Fisher exact, Student t, and log-rank tests
were used to establish statistical signiﬁcance.
Results: Overall, 1407 IARs were performed in 1310
patients with CLI by the same surgeon, 705 (50.2%) in 643
diabetic patients and 702 in 667 nondiabetic patients.
Autogenous vein conduits were used in 87% of the IARs.
There were no perioperative deaths. Diabetic patients had
signiﬁcantly more major (16.7% vs 11.8%; P = .02) and
minor complications (9.7% vs 6.5%; P = .02) than non-
diabetic patients. At 5 and 10 years, there were no signiﬁ-
cant differences between diabetic and nondiabetic patients
in the rates of primary patency (65% and 46% vs 69.5% and
57%; log-rank test, P = .09), secondary patency (76% and
60% vs 80% and 68%; log-rank test, P = .20), limb salvage
(88% and 76% vs 91% and 83%; log-rank test, P = .12)
survival (51% and 34% vs 57% and 38%; log-rank test, P =
.41), or amputation-free survival (45.5% and 27% vs 51%
and 29%; log-rank test, P = .19). The type of conduit did not
affect patency or limb salvage rates in either group.
Conclusions: Diabetic patients receiving IAR for CLI can
have the same survival and amputation-free survival rates
as nondiabetic patients. Their comparable technical and
clinical outcomes strongly demonstrate that diabetics with
CLI can expect the same quantity and quality of life as
nondiabetics with CLI, and aggressive attempts at limb
salvage in patients with diabetes mellitus, including distal
and foot level bypass grafting, should not be discouraged.Impact of runoff grade after endovascular therapy for
femoropopliteal lesions
Seiichi Hiramori, Yoshimitsu Soga, Yusuke Tomoi,
Atsushi Tosaka
Background: We conceived a new method, runoff grade,
to evaluate runoff after endovascular therapy (EVT). We
evaluated the validity of using runoff score based on
angiographic ﬁndings.
Methods: The subjects were 859 consecutive patients
(males, 69%; mean age, 73.0  9.0 years) who underwent
EVT for de novo femoropopliteal lesions at Kokura Memo-
rial Hospital. We evaluated the postprocedural tibial runoff,
named it runoff grade, classiﬁed it into 0 through 2, and
retrospectively assessed the relationship with the outcome
of EVT. Primary, secondary, and assisted primary patency
rates and freedom from major adverse limb events (MALE)
were compared between runoff grades.
Results: The mean follow-up period was 31 
25 months. The lesion length was 91.5  83.0 mm. The rate
328 Abstractsof stent use was 52.0%. The primary patency rates at 1, 2,
and 3 years were 68.1%, 59.1%, and 53.9%; the secondary
patency rates were 90.9%, 88.1%, and 85.9%; the assisted
primary patency rates were 79.4%, 72.6%, and 68.5%; and
freedom from MALE was 72.5%, 64.8%, and 61.0%,
respectively. The primary patency rates at 1, 2, and 3 years
were signiﬁcantly lower in the runoff grade 0 group than in
the other groups (55.5% vs 66.7% and 75.6%; 35.8% vs
57.6% and 69.2%; 35.8% vs 53.3% and 60.9% for grade 0, 1,
2, respectively; log-rank, P < .0001). Secondary patency rate
(78.5% vs 91.8% and 91.8%; 76.3% vs 88.6% and 89.9%;
72.8% vs 86.3% and 88.2%, respectively; P = .015), assisted
primary patency rate (67.0% vs 78.5% and 85.1%; 56.9% vs
71.6% and 79.3%; 47.6% vs 68.0% and 74.8%; respectively,
P = .0002), and freedom from MALE (60.8% vs 71.2% and
79.4%; 44.3% vs 64.0% and 72.6%; 36.6% vs 60.7% and
68.5%, respectively; P < .0001) were also similar. After
adjustment for age, gender, diabetes, hemodialysis, critical
limb ischemia, TransAtlantic Inter-Society Consenus II clas-
siﬁcation, and stent use, runoff grade was an independent
predictor of primary patency.
Conclusions: Vessels with runoff grade 0 had signiﬁcantly
worse cumulative outcomes. Our results suggested that
runoff grade seemed to play an important role to keep the
primary patency.Gender-speciﬁc 30-day outcomes after carotid
endarterectomy and carotid artery stenting in the Society
for Vascular Surgery Vascular Registry
Jeffrey Jim, Ellen D. Dillavou, Gilbert R. Upchurch,
Nicholas H. Osborne, Christopher T. Kenwood,
Flora S. Siami, Rodney A. White, Joseph J. Ricotta
Objective: Although the optimal treatment of carotid
stenosis remains unclear, available data suggest that
women have higher risk of adverse events after carotid
revascularization. We used data from the Society for Vas-
cular Surgery Vascular Registry to determine the effect of
gender on outcomes after carotid endarterectomy (CEA)
and carotid artery stenting (CAS).
Methods: There were 9865 patients (40.6% women) who
underwent CEA (n = 6492) and CAS (n = 3373). The primary
end point was a composite of death, stroke, and myocardial
infarction at 30 days.
Results: There was no difference in age and ethnicity
between genders, but men were more likely to be symp-
tomatic (41.6% vs 38.6%; P < .003). There was a higher
prevalence of hypertension and chronic obstructive pul-
monary disease in women, whereas men had a higher
prevalence of coronary artery disease, history of myocardial
infarction, and smoking history. For disease etiology in CAS,
restenosis was more common in women (28.7% vs 19.7%;
P < .0001), and radiation was higher in men (6.2% vs 2.6%;
P < .0001). Comparing by gender, there were no statistically
signiﬁcant differences in the primary end point for CEA
(women, 4.07%; men, 4.06%) or CAS (women, 6.69%; men,6.80%). There remains no difference after stratiﬁcation by
symptomatology and multivariate risk adjustment.
Conclusions: In this large, real-world analysis, women and
men demonstrated similar results after CEA or CAS. These
data suggest that, contrary to previous reports, women do
not have a higher risk of adverse events after carotid
revascularization.Platelet inhibition by adjunctive cilostazol suppresses the
frequency of cerebral ischemic lesions after carotid artery
stenting in patients with carotid artery stenosis
Ichiro Nakagawa, Takeshi Wada, Hun Soo Park,
Fumihiko Nishimura, Syuichi Yamada, Hiroyuki Nakagawa,
Kimihiko Kichikawa, Hiroyuki Nakase
Objective: Optimal platelet inhibition is an important
therapeutic adjunct in patients with carotid artery stenosis
undergoing carotid artery stenting (CAS). Clopidogrel
resistance is associated with increased periprocedural
thromboembolic complications from neurovascular stent
placement procedures. The addition of cilostazol to dual
antiplatelet therapy (DAT) has been reported to reduce
platelet reactivity and to improve clinical outcomes after
percutaneous coronary intervention. This study was un-
dertaken to evaluate the impact of adjunctive cilostazol in
patients with CAS.
Methods: Platelet function was assessed by light trans-
mittance aggregometry using the VerifyNow assay. Sixty-
four consecutive patients who underwent CAS received
standard DAT, clopidogrel (75 mg daily), and aspirin
(100 mg daily) more than 4 weeks before the procedure.
From 2010 to 2011 (period I), 28 patients underwent CAS
under standard DAT. From 2011 to 2013 (period II), 36
patients prospectively had preoperative assessment of
platelet function, and 13 patients with clopidogrel resist-
ance received adjunctive cilostazol (200 mg daily) in addi-
tion to standard DAT. The incidence of new ipsilateral
ischemic lesions on diffusion-weighted imaging a day after
CAS and ischemic or hemorrhagic events within 30 days
was assessed.
Results: Clopidogrel resistance was indentiﬁed in 12
patients (43%) in period I and 13 patients (36%) in period II
(P = .615). In period II, the addition of cilostazol signiﬁcantly
decreased P2Y12 reaction units and % inhibition (P = .006
and P = .005, respectively), and there was a signiﬁcant
difference in P2Y12 reaction units between the two periods.
New ipsilateral ischemic lesions were signiﬁcantly
decreased in period II (2/36 patients) compared with period
I (7/28 patients; P = .034); however, there was no signiﬁcant
difference in hemorrhagic and thromboembolic events be-
tween the two periods.
Conclusions: Adjunctive cilostazol (triple antiplatelet
therapy) in clopidogrel-resistant patients reduces the rate of
clopidogrel resistance and suppresses new ischemic lesions
without hemorrhagic complications, as compared with
standard DAT. Antiplatelet management based on the
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prevention of perioperative thromboembolic complications
in CAS.Intravascular ultrasound as a clinical adjunct for carotid
plaque characterization
Elizabeth Hitchner, Mohamed A. Zayed, George Lee,
Doug Morrison, Barton Lane, Wei Zhou
Objective: Virtual histology intravascular ultrasound (VH
IVUS) is valuable for estimating minimal lumen diameter
and plaque characterization. The clinical use of IVUS in ca-
rotid intervention is not well characterized. We aim to
evaluate the role of IVUS in carotid plaque characterization
and determine whether it could be predictive of procedure-
related microemboli.
Methods: From July 2010, patients with severe carotid
stenosis who underwent elective carotid stenting pro-
cedures were prospectively enrolled. IVUS evaluation was
performed before stent placement. Patient demographics,
comorbidities, and preoperative images were recorded.
Comparison of pre- and postoperative diffusion-weighted
magnetic resonance images was used to identify thenumber of procedure-related microemboli. IVUS-derived
minimal lumen diameter and vessel wall plaque character-
istics were collected. Univariate and multivariate logistic
regressions were used to search for associations between
IVUS-derived VH data and incidence of microemboli.
Results: A total of 38 high-risk patients receiving carotid
stenting were enrolled. Among them, 25 patients had type I
aortic arches and 17 of the patients were symptomatic
(preoperative stroke or transient ischemic attack). VH IVUS
data did not show strong associations with microemboli,
however, a trend was found between the area of ﬁbrous
tissue and median or more incidence of microemboli (P =
.099). IVUS-deﬁned vessel diameter maximum was asso-
ciated with median or more incidence of microemboli (P =
.042). In addition, median or more incidence of micro-
emboli showed trends with proximal common carotid artery
calciﬁcation (P = .056) and with being over the age of 80
(P = .06). Contralateral carotid occlusion or high-grade
stenosis was associated with postoperative contralateral
microemboli (P = .036).
Conclusions: We demonstrate that periprocedural ca-
rotid IVUS is clinically feasible. VH IVUS may be helpful in
better understanding plaque morphology and determining
optimal stent placement. However, its use in predicting
microembolization remains limited.
